11:31 AM EST, 01/08/2025 (MT Newswires) -- Biofrontera (BFRI) said Wednesday that the last patient completed the one-year follow-up visit in a phase 3 study of the use of Ameluz and RhodoLED photodynamic therapy to treat superficial basal cell carcinoma, a type of skin cancer.

The study evaluated safety and efficacy in 187 patients with at least one clinically and histologically confirmed superficial basal cell carcinomas.

The company said data from the follow-up will be included in its supplemental new drug application submission to the US Food and Drug Administration, expected in Q3.

Biofrontera shares were up nearly 12% in recent trading.

Price: 1.24, Change: +0.13, Percent Change: +11.71